Table 1 Population demographics according to learning curve phases
Demographics | Total (n = 182) | Preliminary phase (1–91) | Transition phase (91–125) | Proficient phase (125–182) | P-value |
|---|---|---|---|---|---|
Sex, n [%] | 0.011 | ||||
Male | 146 [80.2] | 69 [75.8] | 25 [71.4] | 54 [93.1] | |
Female | 36 [19.8] | 22 [24.2] | 10 [28.6] | 4 [6.9] | |
Age, y | 62.4 (8.9) | 62.3 (8.4) | 61.8 (9.7) | 61.5 (9.1) | 0.593 |
BMI | 21.9 (2.9) | 22.1 (2.9) | 22.1 (2.4) | 21.5 (5.2) | 0.482 |
Smoking status, n [%] | 0.103 | ||||
Never | 81 [44.5] | 43 [47.3] | 20 [57.1] | 19 [32.8] | |
Previous | 26 [14.3] | 10 [11.0] | 3 [8.6] | 13 [22.4] | |
Current | 75 [41.2] | 38 [41.8] | 12 [34.3] | 26 [44.8] | |
aCCI Median [IQR] | 2 (1–3) | 2 (1–3) | 2 (1–3) | 2 (1–3) | 0.729 |
ECOG, n [%] | 0.485 | ||||
0 | 76 [41.8] | 40 [44.0] | 17 [48.6] | 20 [34.5] | |
1 | 106 [58.2] | 51 [56.0] | 18 [51.4] | 38 [65.5] | |
Histology, n [%] | 0.679 | ||||
Squamous | 175 [96.2] | 86 [94.5] | 34 [97.1] | 57 [98.3] | |
Others | 7 [3.8] | 5 [5.5] | 1 [2.9] | 1 [1.7] | |
Clinical T, n [%] | 0.110 | ||||
cT1 | 32 [17.6] | 20 [22.0] | 7 [20.0] | 5 [8.6] | |
cT2 | 38 [20.9] | 21 [23.1] | 8 [22.9] | 9 [15.5] | |
cT3 | 112 [61.5] | 50 [54.9] | 20 [57.1] | 44 [75.9] | |
Clinical N, n [%] | 0.034 | ||||
cN- | 109 [59.9] | 49 [53.8] | 19 [54.3] | 15 [25.9] | |
cN + | 73 [40.1] | 42 [46.2] | 16 [45.7] | 43 [74.1] | |
Neoadjuvant, n [%] | < 0.001 | ||||
No therapy | 78 [42.9] | 52 [57.1] | 17 [48.6] | 11 [19.0] | |
Chemotherapy | 78 [42.9] | 33 [36.3] | 12 [34.3] | 33 [56.9] | |
Combined chemotherapy | 26 [14.3] | 6 [6.6] | 6 [17.1] | 14 [24.1] | |
Radiotherapy | 17 [9.3] | 6 [6.6] | 4 [11.4] | 7 [12.1] | |
Immunotherapy | 9 [5.0] | 0 [0.0] | 2 [5.7] | 7 [12.1] | |
Tumour location, n [%] | 0.199 | ||||
Upper | 25 [13.7] | 12 [13.2] | 5 [14.3] | 8 [13.8] | |
Middle | 68 [37.4] | 28 [30.8] | 12 [34.3] | 29 [50.0] | |
Lower | 89 [48.9] | 51 [56.0] | 18 [51.4] | 21 [36.2] |